Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s)
Prif Awduron: | Sandham, D, Chen, W, Hardman, C, Luo, J, Xue, L, Ogg, G, Erpenbeck, V |
---|---|
Fformat: | Conference item |
Iaith: | English |
Cyhoeddwyd: |
Wiley
2019
|
Eitemau Tebyg
-
Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s)
gan: Chen, W, et al.
Cyhoeddwyd: (2018) -
Fevipiprant, a selective prostaglandin D-2 receptor 2 antagonist, potently inhibits chemotaxis and cytokine production by group 2 innate lymphoid cells
gan: Xue, L, et al.
Cyhoeddwyd: (2018) -
Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function
gan: Hardman, C, et al.
Cyhoeddwyd: (2019) -
Fevipiprant, a selective prostaglandin D(2)receptor 2 antagonist, potently inhibits chemotaxis and cytokine production by Tc2 cells (type-2 CD8(+)lymphocytes)
gan: Xue, L, et al.
Cyhoeddwyd: (2019) -
IL-6 effector function of group 2 innate lymphoid cells (ILC2) is NOD2 dependent
gan: Hardman, CS, et al.
Cyhoeddwyd: (2021)